At the cutting edge of treatment of cancer and autoimmune diseases, China is becoming a core position for the development and testing of innovative cell therapies. In particular, it has shown a leading trend in the world in the development of next-generation in-vivo CAR-T cell therapies. A report recently published in “Nature” magazine cites a comprehensive analysis of the development of in vivo CAR-T therapy, pointing out that although basic and pre-clinical research in this field is mainly completed by teams from the US, Germany and other countries, China is moving extremely rapidly in terms of clinical transformation. Currently, 82% of the 140 types of in vivo CAR-T drugs currently being tested on animals and humans around the world are being developed by the Chinese team.

At the cutting edge of treatment of cancer and autoimmune diseases, China is becoming a core position for the development and testing of innovative cell therapies. In particular, it has shown a leading trend in the world in the development of next-generation in-vivo CAR-T cell therapies. A report recently published in “Nature” magazine cites a comprehensive analysis of the development of in vivo CAR-T therapy, pointing out that although basic and pre-clinical research in this field is mainly completed by teams from the US, Germany and other countries, China is moving extremely rapidly in terms of clinical transformation. Currently, 82% of the 140 types of in vivo CAR-T drugs currently being tested on animals and humans around the world are being developed by the Chinese team.